Major acceleration of Annogen’s SuRE technology in seed and ag-biotech sector

Annogen is launcing its proprietary SuRE platform, which is used for functional annotation and improvement of promoters and enhancers, for applications in crop engineering. The powerful platform provides a massive-scale “blueprint” of a crop’s genetic regulatory landscape to pinpoint the specific mutations that unlock key traits like drought/pest resistance and increased yield. Annogen’s SuRE platform can for instance rapidly characterize all variants in gene promotors that control or enhance expression of specific genes and traits without editing the natural, coding genes. Using this information, increased gene expression and trait improvement can subsequently be established via TILLING or gene editing (GE).

To help accelerate our contribution in the Ag-Biotech field, we are proud to announce that industry leader Dr. Arjen van Tunen, former CEO of KeyGene, will support and advice our Ag team. His expertise and vision will be instrumental as we build on our strong foundation and collaborations in the seed industry.

Learn more about FACE™

In the past few years we have validated our platform with leading seed and Ag-Biotech companies. We could show for instance that gene expression of crucial genes can be upregulated via single point mutations in specifically identified regulatory regions with factors more than 10-fold. We will now expand our efforts to help the seed industry to develop the resilient, high-performance crops our world needs.”, says Dr. Joris van Arensbergen, CEO and founder of Annogen.

Annogen is ready to provide our new proprietary tools for genetically engineered crop improvement and to assist in driving sustainable agriculture forward.

Speak with an expert

Why promoter design is no longer just an expression checkbox, it’s the key to therapeutic endurance.

Why promoter design is no longer just an expression checkbox, it’s the key to therapeutic endurance.

Promoter design is becoming central to durable cell and gene therapy, as the field moves beyond delivery and toward precise expression control. Standard promoters like CMV or PGK often fail to solve key clinical challenges: off-target activity, “always-on” expression that can drive cellular exhaustion, and epigenetic silencing that shuts therapies down in vivo. Annogen’s SuRE™ platform addresses these bottlenecks by experimentally screening millions of non-coding DNA fragments in relevant models and refining designs with machine learning. The result is not a generic promoter, but a validated, non-viral promoter tailored for the specific tissue, condition, and therapeutic context.

VectorY’s Clinical Milestone and the Shift Toward Experimentally-Validated Promoters

VectorY’s Clinical Milestone and the Shift Toward Experimentally-Validated Promoters

The first patient dosing in VectorY Therapeutics’ PIONEER-ALS trial marks a definitive shift in gene therapy, moving past the “conservative” reliance on blunt viral promoters and the “digital guesses” of AI. While many rely on algorithms built from incomplete and insensitive data, VTx-002 is powered by an Annogen genome-derived promoter discovered through rigorous, large-scale experimental validation. This milestone proves that true therapeutic precision isn’t predicted in a black box—it is found by interrogating the genome directly to deliver the biological truth required for the clinic.

Technology

 

Solutions

 

Annogen